Sotac Pharmaceuticals Limited
NNSE:SOTAC92.00
INR
+1.95
(+2.17%)
Sotac Pharmaceuticals Limited
NSE:SOTAC
(National Stock Exchange of India)
Recent
price
92.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Sotac Pharmaceuticals Ltd (SOTAC.NS) manufactures and sells a broad range of pharmaceutical products on a contract manufacturing and loan licensing basis across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins; it also produces nutraceuticals and food products on a contract basis, encompassing dosage forms such as non-beta-lactam and beta-lactam tablets (coated and uncoated), capsules, oral liquids, dry syrups, nasal sprays, relief sprays, and creams. The company supplies products across 14 states in India and exports to over 20 countries worldwide. Incorporated in 2015 and headquartered at Plot No. PF-21 & PF-22/A, near ACME Pharma, opposite Teva Pharma, Sanand GIDC-II, Ahmedabad, Gujarat 382110, India, Sotac Pharmaceuticals operates in the pharmaceuticals and biotechnology sector, targeting pharmaceutical companies for formulation development, clinical batch production, and commercial-scale manufacturing. Its subsidiaries include Sotac Healthcare Private Limited (71% holding), Sotac Research Private Limited (100% holding), and Sotac Lifesciences Private Limited. In 2022, the company expanded through acquisitions of majority stakes in Sotac Healthcare Private Limited and Sotac Research Private Limited, integrating them as subsidiaries, and initiated operations at SOTAC Lifesciences with a 51% stake; more recently, in December 2025, it secured a purchase order worth Rs 17.4 million from Cadila Pharmaceuticals for Levozet M Tablets, with staggered delivery scheduled for late January 2026. The company listed on the National Stock Exchange (NSE SME) in April 2023 via an initial public offering of up to 3 million equity shares and held its 10th Annual General Meeting in September 2025, approving a final dividend of Rs 0.10 per share.